Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Pfizer
|
| gptkbp:acquisitionYear |
2004
|
| gptkbp:CEO |
Sheldon Koenig
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
cardiometabolic diseases
cholesterol management |
| gptkbp:foundedBy |
Roger Newton
|
| gptkbp:foundedYear |
1998
|
| gptkbp:headquartersLocation |
gptkb:Ann_Arbor,_Michigan,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Esperion Therapeutics
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
Nexletol
Nexlizet |
| gptkbp:numberOfEmployees |
approximately 200 (as of 2023)
|
| gptkbp:publiclyTraded |
gptkb:NASDAQ
|
| gptkbp:re-establishedInYear |
2008
|
| gptkbp:stockSymbol |
gptkb:ESPR
|
| gptkbp:therapeuticArea |
lipid management
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
https://www.esperion.com/
|
| gptkbp:bfsParent |
gptkb:Alta_Partners
|
| gptkbp:bfsLayer |
7
|